Clinical Trial Update: A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. [Phase 2]

View source ↗

Summary

Phase 2 study evaluating olutasidenib in IDH1-mutated clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes including chronic m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clonal Cytopenia of Undetermined Significance
• Myelodysplastic Syndromes
• Myelomonocytic Leukemia

Drugs mentioned

• Olutasidenib (olutasidenib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia | Phase 2 | Status: RECRUITING